C69.31: Malignant neoplasm of right choroid

C69.31, malignant neoplasm of right choroid, is listed as a covered diagnosis in 14 Medicare billing and coding articles that apply to 91 HCPCS Level II codes, including G0340 (Image-guided robotic linear accelerator-based stereotactic…), G0339 (Image-guided robotic linear accelerator-based stereotactic…), J0881 (Injection, darbepoetin alfa, 1 microgram (non-esrd use)). 4 of these codes have a 2026 DMEPOS fee schedule amount; E0783 pays $9,917.33 to $11,667.45 (NU) depending on the state. The articles come from 5 Medicare contractors. A listed diagnosis supports medical necessity only; coverage still depends on the LCD's criteria and on documentation in the medical record.

HCPCS Level II codes with C69.31 as a covered diagnosis

CodeDescriptionMedicare coverageDMEPOS fee 2026 (state range)Articles listing it
G0340Image-guided robotic linear accelerator-based stereotactic radiosurgery, delivery including collimator changes and custom plugging, fractionated treatment, all lesions, per session, second through fifth sessions, maximum five sessions per course of treatmentCarrier judgment—2
G0339Image-guided robotic linear accelerator-based stereotactic radiosurgery, complete course of therapy in one session or first session of fractionated treatmentCarrier judgment—2
J0881Injection, darbepoetin alfa, 1 microgram (non-esrd use)Special coverage instructions apply—3
J0885Injection, epoetin alfa, (for non-esrd use), 1000 unitsSpecial coverage instructions apply—3
Q5106Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 unitsSpecial coverage instructions apply—3
J0882Injection, darbepoetin alfa, 1 microgram (for esrd on dialysis)Special coverage instructions apply—3
Q5105Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for esrd on dialysis), 100 unitsSpecial coverage instructions apply—3
J0890Injection, peginesatide, 0.1 mg (for esrd on dialysis)Carrier judgment—3
Q4081Injection, epoetin alfa, 100 units (for esrd on dialysis)Special coverage instructions apply—3
G0563Stereotactic body radiation therapy, treatment delivery, per fraction to 1 or more lesions, including image guidance and real-time positron emissions-based delivery adjustments to 1 or more lesions, entire course not to exceed 5 fractionsCarrier judgment—1
C8900Magnetic resonance angiography with contrast, abdomenSpecial coverage instructions apply—2
C8901Magnetic resonance angiography without contrast, abdomenSpecial coverage instructions apply—2
C8902Magnetic resonance angiography without contrast followed by with contrast, abdomenSpecial coverage instructions apply—2
C8909Magnetic resonance angiography with contrast, chest (excluding myocardium)Special coverage instructions apply—2
C8910Magnetic resonance angiography without contrast, chest (excluding myocardium)Special coverage instructions apply—2
C8911Magnetic resonance angiography without contrast followed by with contrast, chest (excluding myocardium)Special coverage instructions apply—2
C8912Magnetic resonance angiography with contrast, lower extremitySpecial coverage instructions apply—2
C8913Magnetic resonance angiography without contrast, lower extremitySpecial coverage instructions apply—2
C8914Magnetic resonance angiography without contrast followed by with contrast, lower extremitySpecial coverage instructions apply—2
C8918Magnetic resonance angiography with contrast, pelvisSpecial coverage instructions apply—2
C8919Magnetic resonance angiography without contrast, pelvisSpecial coverage instructions apply—2
C8920Magnetic resonance angiography without contrast followed by with contrast, pelvisSpecial coverage instructions apply—2
J0888Injection, epoetin beta, 1 microgram, (for non esrd use)Special coverage instructions apply—2
J0887Injection, epoetin beta, 1 microgram, (for esrd on dialysis)Special coverage instructions apply—2
J9267Injection, paclitaxel, 1 mgSpecial coverage instructions apply—1

66 more codes are listed. See every code with payment by region in Caduvo.

Medicare policy articles listing C69.31

A diagnosis listed as covered in a billing and coding article supports medical necessity for the article's codes; it does not guarantee payment. Coverage depends on the LCD's criteria, the contractor's jurisdiction and documentation in the medical record.

Other C69 diagnoses (Malignant neoplasm of eye and adnexa)

Frequently asked questions

Does Medicare cover C69.31 (Malignant neoplasm of right choroid)?

Medicare covers items and services, not diagnoses. 14 Medicare billing and coding articles list C69.31 as a covered diagnosis for 91 HCPCS Level II codes: the diagnosis can support medical necessity for those codes, but payment still depends on the LCD's coverage criteria and the medical record.

Which HCPCS codes can be billed with ICD-10 C69.31?

The Level II codes from the policies most specific to this diagnosis are G0340 (Image-guided robotic linear accelerator-based stereotactic…, 2 articles); G0339 (Image-guided robotic linear accelerator-based stereotactic…, 2 articles); J0881 (Injection, darbepoetin alfa, 1 microgram (non-esrd use), 3 articles); J0885 (Injection, epoetin alfa, (for non-esrd use), 1000 units, 3 articles); Q5106 (Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for…, 3 articles). Code choice depends on the item supplied; check each code's descriptor.

What does Medicare pay for equipment billed with C69.31?

Under the 2026 DMEPOS fee schedule (non-rural state fees): E0783 $9,917.33 to $11,667.45 (NU); E0786 $10,969.75 to $11,380.88 (NU); E0782 $5,200.92 to $6,118.73 (NU); E0785 $572.38 to $673.39 (KF). Medicare pays 80% of the allowed amount after the Part B deductible.

Which Medicare policy articles list C69.31?

A56874 (Billing and Coding: Stereotactic Radiation Therapy: Stereotactic Radiosurgery (SRS) and Stereotactic Body Radiation Therapy (SBRT)); A52450 (Billing and Coding: Paclitaxel (e.g., Taxol®/Abraxane ™)); A59350 (Billing and Coding: Radiation Therapies), and 11 more articles.

What is ICD-10-CM code C69.31?

C69.31 is the ICD-10-CM code for malignant neoplasm of right choroid, in category C69 (Malignant neoplasm of eye and adnexa), chapter 2: Neoplasms.

Next steps

Sources: CMS Medicare Coverage Database billing and coding articles (covered ICD-10 code lists and HCPCS links); ICD-10-CM FY2026; CMS HCPCS Level II release October 2026; CMS DMEPOS fee schedule 2026 (non-rural state fees). Not billing or legal advice.

Chapter 2: Neoplasms · All diagnoses · HCPCS lookup